High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ-Aminobutyric Acid A/Benzodiazepine Receptor Complex
摘要:
A series of imidazo[1,5-alpha]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies racing from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.
The present invention relates to 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives of the formula: ##STR1## to their preparation and to the pharmaceutical compositions in which they are present. These derivatives have an affinity for the vasopressin and oxytocin receptors.
An invention relating to Imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group and which are useful as anxiolytic and sedative/hypnotic agents.
一种涉及咪唑并[1,5-a]喹喔啉(I)的发明,不含内环羰基,并且可用作抗焦虑和镇静/催眠剂。
4,5-cyclicimidazo[1,5-A]quinoxalines
申请人:Pharmacia & Upjohn Company
公开号:US05668282A1
公开(公告)日:1997-09-16
The invention discloses imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group that are useful as anxiolytic and sedative/hypnotic agents.
The invention discloses imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group that are useful as anxiolytic and sedative/hypnotic agents.
Dérivés de 1-benzènesulfonyl-1,3-dihydro-2H-benzimidazol-2-one, leur préparation, les compositions pharmaceutiques en contenant
申请人:SANOFI
公开号:EP0636614A1
公开(公告)日:1995-02-01
La présente invention concerne des dérivés de 1-benzènesulfonyl-1,3-dihydro-2H-benzimidazol-2-one de formule :
leur préparation et les compositions pharmaceutiques en contenant.
Ces composés ont une affinité pour les récepteurs de la vasopressine et de l'ocytocine.